Covalon Technologies Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brent Ashton
- Full Time Employees
- 105
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1660 Tech Avenue Mississauga ON Canada L4W 5S7
- IPO Date
- Apr 18, 2007
- CIK
- 0001789397
- Website
- covalon.com
- Similar Companies
- Business
- Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF) develops, manufactures and markets patented medical products focused on advanced wound care, infection management, vascular access, perioperative care and medical device coatings. The company offers collagen matrix-based wound dressings such as ColActive PLUS for chronic and infected wounds including diabetic ulcers, pressure ulcers and burns; antimicrobial silicone adhesive products including IV Clear, a dual-antimicrobial clear IV dressing, SurgiClear for surgical use, VALGuard for vascular access line protection and CovaClear for sensitive skin; CovaView and CovaWound dressings; together with customized coating solutions via its photo-polymerization platform. Founded in 2004 and headquartered in Mississauga, Ontario, Canada, Covalon serves hospitals, wound care centers, burn centers, long-term care facilities and home health agencies primarily in the United States, Canada, Latin America, the Middle East and internationally. In 2025, the company reports strong revenue growth exceeding 40% year-to-date in vascular access, surgical consumables and international sales; achieves its fifth consecutive quarter of profitability with gross margins of 55-60%; maintains over $18 million in cash reserves and zero debt; retains 100% of its top 50 U.S. hospital customers; signs a major distribution agreement with Paul Hartmann USA for ColActive PLUS; engages Origin Merchant Partners to pursue mergers, acquisitions and partnerships, primarily in North America; and announces its first-ever dividend payment.
Company News
Covalon Technologies Ltd. (COV:CA) Q3 2026 Earnings Call Transcript
Covalon Reports Fiscal 2026 Third Quarter Results
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2026 Results
Covalon Announces Appointment of New Director and DSU Grants
Covalon Technologies Ltd. (COV:CA) Q2 2026 Earnings Call Transcript
Covalon Reports 2026 Second Quarter Results
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
Comparing Solana (NASDAQ:HSDT) and Covalon Technologies (OTCMKTS:CVALF)
Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
Covalon Announces Grant of Deferred Share Units
Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
Covalon Technologies Ltd. (COV:CA) Shareholder/Analyst Call Transcript
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
Covalon Technologies Ltd. (COV:CA) Q1 2026 Earnings Call Transcript
Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results
Covalon Technologies (OTCMKTS:CVALF) Shares Up 10.5% – What’s Next?
Covalon Technologies Ltd. (COV:CA) Q4 2025 Earnings Call Transcript